Intensified insulin therapy
ProcedureOther names: continuous insulin infusion
NCT Number: NCT02863276
Background Surgical injury provokes a stress response. These pathways mediated by stress hormones and cytokines cause a catabolic state. The loss of body cell mass may result in prolonged convalescence and increased morbidity. Protein catabolism after colorectal surgery is even more increased in patients with type 2 diabetes mellitus. Epidural blockade, by reducing the intensity of the catabolic response, improves substrate utilization after surgery in non-diabetic patients. This effect is even more pronounced in diabetic patients receiving amino acids.
The aim of the study is to explore the effect of two different protocols to manage blood glucose control on glucose and protein metabolism in patients with type 2 diabetes mellitus undergoing colon surgery and receiving epidural analgesia and perioperative feeding with amino acids. The following hypotheses are tested:
1. Tight perioperative blood glucose control with intensified insulin therapy compared to standard blood glucose control in presence of general anesthesia with epidural analgesia and amino acid infusion would reduce endogenous glucose production and leucine oxidation. 2. Tight blood glucose control and perioperative infusion of amino acids induce a more positive protein balance compared to standard blood glucose control by better oxidative glucose utilization and redirecting amino acids from oxidative to synthetic pathways.
Material and Methods A total of 20 patients with diabetes mellitus type 2 undergoing elective colorectal surgery will be admitted to the study. Patients will be randomly assigned to receive standard blood glucose control (blood glucose target <10 mmol*l-1; control group; cytotoxic T lymphocyte (CTL) group, n=8) or to receive tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1; intensified insulin group; II group, n=8). All patients will receive general anesthesia and an epidural catheter for perioperative analgesia. During surgery (intraoperative state) and immediately after surgery (postoperative state) when receiving an amino acid infusion protein and glucose kinetics will be assessed using a stable isotope technique with L-[1-13C]leucine and [6,6-2H2]glucose and circulating concentrations of glucose, glucagon, insulin and cortisol will be measured. The primary endpoints of the study will be protein balance. Sample size is set to ensure at least 80% power at a significance level of 0.05.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
see information below
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: continuous insulin infusion
Time frame: Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
Time frame: Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine
Time frame: Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine
Time frame: Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose
Time frame: Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose and plasma glucose measurement
Time frame: Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
Time frame: Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
Time frame: Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
Time frame: Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period
Time frame: Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose
Time frame: Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose and plasma glucose measurement
University Hospital, Basel, Switzerland
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01336777
Body Weight, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT02258698
Diabetes Mellitus, Diabetes Mellitus Type 2
Basel, Canton of Basel-City, Switzerland
View Trial DetailsNCT01121172
Body Weight, Diabetes Mellitus
Thessaloniki, Greece
View Trial DetailsNCT00401453
Diabetes Mellitus, Diabetes Mellitus Type 2
Mannheim, Baden-Wurttemberg, Germany
View Trial Details